Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

67053 1513184208HCLSReviewBulgariaDecember2017.pdf
Energy Boardroom

Type your email in the box below to read this content NOW:

Interview

Mads Stoustrup – General Manager, Novo Nordisk Switzerland

Mads StoustrupDiabetes is well managed in Switzerland’s patient-centric healthcare system, yet with new data showing Novo Nordisk’s GLP-1 has strong cardiovascular benefits, the company is working to drive a change in treatment standards.

Switzerland has been recognized as the most innovative country in the world, and is known to have a highly innovative and high quality healthcare system. How is this translated into the way diabetes is treated in the country?

The Swiss healthcare system is certainly of very high quality, with patients generally having broad access to innovative treatments and high quality care. Patients with diabetes are treated by approximately 220 specialist endocrinologists, with between 2000 and 3000 GPs treating primarily type II patients on their own. Significantly, the system is by design very patient-centric, with patients and their treating physicians having a high degree of input over what products to use and how to treat a patient. These patients and physicians can really look at all the available treatment options and select the one that fits their situation best, and in general they tend to prefer high quality and innovative products. This is something we at Novo Nordisk see clearly when we bring new innovations to Swiss patients, and thus we have seen high rates of adoption and penetration of our new generation of insulin (Tresiba®, Ryzodeg®) and combination products (Xultophy®) based on the insulin degludec molecule..

LATEST ISSUE

DOWNLOAD

Most Read

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: